Clinical Trial

A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-30
Trial Details
NCT Number NCT07564154
Lead Sponsor Kali Therapeutics, Inc.
Conditions Rheumatoid Arthritis (RA)
Enrollment 27 participants
Start Date 2026-07-13
Primary Completion 2027-12 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-11